DOCSLIB.ORG

Isoprenyl Carboxyl Methyltransferase Inhibitors: a Brief Review Including Recent Patents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Isoprenyl Carboxyl Methyltransferase Inhibitors: a Brief Review Including Recent Patents Amino Acids (2017) 49:1469–1485 DOI 10.1007/s00726-017-2454-x REVIEW ARTICLE Isoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents Woo Seok Yang1 · Seung‑Gu Yeo2 · Sungjae Yang1 · Kyung‑Hee Kim3 · Byong Chul Yoo3 · Jae Youl Cho1 Received: 10 June 2017 / Accepted: 14 June 2017 / Published online: 19 June 2017 © The Author(s) 2017. This article is an open access publication Abstract Among the enzymes involved in the post-transla- based on formulas other than the indole base. However, fur- tional modifcation of Ras, isoprenyl carboxyl methyltrans- ther optimization of chemicals targeted to functional groups ferase (ICMT) has been explored by a number of research- is needed to improve the characteristics of ICMT inhibi- ers as a signifcant enzyme controlling the activation of Ras. tors related to their application as drugs, such as solubility, Indeed, inhibition of ICMT exhibited promising anti-cancer effectiveness, and safety, to facilitate clinical use. activity against various cancer cell lines. This paper reviews patents and research articles published between 2009 and Keywords ICMT inhibitor · Cancer · Methylation · 2016 that reported inhibitors of ICMT as potential chemo- Cysmethynil · Ras therapeutic agents targeting Ras-induced growth factor signaling. Since ICMT inhibitors can modulate Ras signal- ing pathway, it might be possible to develop a new class of Introduction anti-cancer drugs targeting Ras-related cancers. Research- ers have discovered indole-based small-molecular ICMT The post-translational modifcation of Ras family members inhibitors through high-throughput screening. Researchers is a crucial step in inducing translocation of Ras proteins at Duke University identifed a prototypical inhibitor, cys- from the endoplasmic reticulum to the plasma membrane methynil. At Singapore University, Ramanujulu and his for management of cell proliferation triggered by growth colleagues patented more potent compounds by optimizing factor signaling. Mutations in Ras family proteins (e.g., cysmethynil. In addition, Rodriguez and Stevenson at Uni- K-RAS) are also closely related to the incidence of vari- versidad Complutense De Madrid and Cancer Therapeu- ous types of cancers in humans, such as pancreatic cancer tics CRC PTY Ltd., respectively, have developed inhibitors (Downward 2003; Pylayeva-Gupta et al. 2011). Normally, a series of post-translational modifcations of Ras proteins are a prerequisite for localization of Ras in the plasma Woo Seok Yang and Seung-Gu Yeo were contributed equally. membrane; however, mutations in Ras proteins can induce * Byong Chul Yoo uncontrolled activation of Ras signaling pathways and [email protected] Ras-mediated oncogenesis in the cell membrane. The post- * Jae Youl Cho translational modifcation of Ras frst requires farnesylation [email protected] or geranylgeranylation of the C-terminal CAAX motif, in which covalent bonding of farnesyl or geranylgeranyl iso- 1 Department of Genetic Engineering, Sungkyunkwan prenoid lipids to the cysteine residue of CAAX is mediated University, 2066 Seobu‑ro, Jang‑gu, Suwon 16419, Republic of Korea by farnesyl transferase (FTase) or geranylgeranyl trans- ferase (GGTase I), respectively, as summarized in Fig. 1 2 Department of Radiation Oncology, Soonchunhyang University College of Medicine, Soonchunhyang University (Winter-Vann and Casey 2005; Clarke 1988). During this Hospital, Cheonan 31151, Republic of Korea step, the CAAX endoprotease RCE1 cleaves the three C-ter- 3 Biomarker Branch, Research Institute, National Cancer minal amino acids (–AAX) (Ashby 1998), and isoprenyl Center, Goyang 10408, Republic of Korea carboxyl methyltransferase (ICMT) methylates a prenylated 1 3 1470 W. S. Yang et al. Fig. 1 Schematic diagram of the RAS/ICMT regulatory pro- cess in a growth factor-inducing Farnesyl group Farnesyl group signaling cascade. FTase S S GF farnesyltransferase, RCE1 Ras- converting CAAX endopepti- Ras-CAAX-COOH Ras-C-COOH dase 1, ICMT isoprenylcysteine RCE1 methyltransferase, AdoMet CH3 Farnesyl group FTase AdoMet S-adenosyl-L-methionine, ICMT AdoHcy S-adenosyl-L-homo- SH S cysteine, GF growth factor Ras-CAAX-COOH AdoHcy Ras-C-COOCH3 Ras-mediated proliferation-regulatory signaling cysteine (Bergo et al. 2000). Isoprenyl carboxyl methylated frst class of these inhibitors includes S-adenosyl-L-ho- proteins anchor to the cell membrane (Eisenberg et al. 2013) mocysteine (AdoHcy) and its precursors. During meth- and infuence cell signaling pathways. (Bergo et al. 2004; ylation, S-adenosyl-L-methionine (AdoMet) donates a Goodman et al. 1990). ICMT (MW 32 kDa) is essential for methyl group to the substrate proteins and is converted post-translational modifcation of Ras proteins and is local- to AdoHcy (Pylayeva-Gupta et al. 2011; Anderson et al. ized in the endoplasmic reticulum (Zhang and Casey 1996). 2005; Kim et al. 2013; Perez-Sala et al. 1992), a by-prod- Since Ras plays an important role in cancerous signaling uct that acts in a negative feedback reaction and leads pathways, ICMT is also a substantial focus of studies on to reduced enzyme activity of methyltransferase until it anti-cancer agents (Wahlstrom et al. 2008). Suppression of is cleaved by AdoHcy hydrolase (Shi and Rando 1992; the carcinogenic transformation of RAS by inhibition of the Kramer et al. 2003). Therefore, AdoHcy suppresses the enzymes involved in farnesylation or geranylgeranylation activity of ICMT by acting as a non-selective inhibitor of has been studied for treatment of cancer. There are several other methyltransferases (Winter-Vann et al. 2003), and inhibitors of FTase, including lonafarnib (IC 1.9 nM) specifc inhibitors of ICMT are still needed for treatment. 50 = and tipifarnib (IC 7.9 nM) (Basso et al. 2006). Although N-Acetyl-S-farnesyl-L-cysteine (AFC) and N-acetyl- 50 = some inhibitors of FTase have shown inhibitory activities S-geranylgeranyl-L-cysteine (AGGC) can competitively in mouse models, they had no notable effect on the clinical bind to the same substrate tunnel of farnesylated proteins. score in cancer patients. Moreover, the geranylgeranylated These structural analogs of prenylcysteine represent the Ras proteins maintain biological activities when FTase is second class of ICMT inhibitors by acting as actual sub- blocked by inhibitors, limiting the effects of those inhibitors strates that can compete with Ras (Henriksen et al. 2005). (Anderson et al. 2005; Doll et al. 2004; Mazieres et al. 2004; In fact, there are three structural mimics of AFC. The Lene 2009). Numerous reports have also demonstrated that frst analog of AFC, which has a sulphonamide linkage inhibition of ICMT leads to an anti-proliferative effect in in place of an amide bond, had an IC 50 value of 8.8 μM cancer (Clarke 1988; Bos 1989; Bishop et al. 2003; Gibbs in a vapor diffusion assay (Hrycyna and Clarke 1990). et al. 1994). Pharmacologic or genetic inactivation of ICMT The other analog of AFC has a triazole moiety in place resulted in cell cycle arrest and apoptosis (Bergo et al. of an allylic thioether, which can be easily degraded by 2000, 2004). Therefore, the strategy of suppressing ICMT enzymatic and chemical processes. This analog has an with chemical inhibitors could be considered an alternative IC50 value of 19.4 μM. The third structural mimic pos- therapeutic approach targeting Ras-mediated tumorigenic sesses an aryl alkyl moiety in the farnesyl side chain responses (Teh et al. 2014). of AFC instead of two isoprenoid units and has an IC 50 value of 34.6 μM (Ramanujulu et al. 2013; Buchanan et al. 2007, 2008a, b). The third class of ICMT inhibi- ICMT inhibitor classes tors includes molecules that have a low molecular weight (<900 Da) and are utilized as drugs due to their rapid dif- Isoprenyl carboxyl methyltransferase inhibitors are fusion through the cell membrane (Macielag 2012). Cys- divided into three classes based on their properties. The methynil (2-[5-(3-methylphenyl)-l-octyl-lH-indolo-3-yl] 1 3 Isoprenyl carboxyl methyltransferase inhibitors: a brief review including recent patents 1471 acetamide), which was identifed from 10,000 compounds The subsections are organized in chronological order by in the chemical library, is a representative small-molecu- patent applicant. lar inhibitor that competes with isoprenylated cysteine of other CAAX-containing proteins, but not AdoMet (Lene Purdue research foundation 2009). Cysmethynil induces incorrect localization of Ras and interrupts the signaling pathway of cancer cells. Despite fndings that FTase is a key enzyme in the post- Consequently, cysmethynil causes autophagic cell death translational modifcation of Ras proteins and other major through pharmacological inhibition of ICMT (Winter- causative enzymes involved in 30% of human cancers, Vann et al. 2003; Henriksen et al. 2005; Wang et al. 2008; numerous human tumors associated with mutation of K-Ras Clarke and Tamanoi 2004; Baron et al. 2007). Because are resistant to FTase inhibitors. In the presence of FTase the desired concentration of a drug in circulation is deter- inhibitors, the decreased biological activity of farnesylated mined by its solubility, this measure is a very important K-Ras is compensated for by another form of K-Ras post- aspect of drug development (Savjani et al. 2012). Cys- translational modifcation: geranylgeranylation by GGTase methynil is insoluble in water and has high lipophilicity I. Therefore, many research centers and institutes have and structural fexibility and is, therefore, considered to focused on the identifcation
Load more

Recommended publications
  • The Self-Inhibitory Nature of Metabolic Networks and Its Alleviation Through Compartmentalization
    ARTICLE Received 30 Oct 2016 | Accepted 23 May 2017 | Published 10 Jul 2017 DOI: 10.1038/ncomms16018 OPEN The self-inhibitory nature of metabolic networks and its alleviation through compartmentalization Mohammad Tauqeer Alam1,2, Viridiana Olin-Sandoval1,3, Anna Stincone1,w, Markus A. Keller1,4, Aleksej Zelezniak1,5,6, Ben F. Luisi1 & Markus Ralser1,5 Metabolites can inhibit the enzymes that generate them. To explore the general nature of metabolic self-inhibition, we surveyed enzymological data accrued from a century of experimentation and generated a genome-scale enzyme-inhibition network. Enzyme inhibition is often driven by essential metabolites, affects the majority of biochemical processes, and is executed by a structured network whose topological organization is reflecting chemical similarities that exist between metabolites. Most inhibitory interactions are competitive, emerge in the close neighbourhood of the inhibited enzymes, and result from structural similarities between substrate and inhibitors. Structural constraints also explain one-third of allosteric inhibitors, a finding rationalized by crystallographic analysis of allosterically inhibited L-lactate dehydrogenase. Our findings suggest that the primary cause of metabolic enzyme inhibition is not the evolution of regulatory metabolite–enzyme interactions, but a finite structural diversity prevalent within the metabolome. In eukaryotes, compartmentalization minimizes inevitable enzyme inhibition and alleviates constraints that self-inhibition places on metabolism. 1 Department of Biochemistry and Cambridge Systems Biology Centre, University of Cambridge, 80 Tennis Court Road, Cambridge CB2 1GA, UK. 2 Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, UK. 3 Department of Food Science and Technology, Instituto Nacional de Ciencias Me´dicas y Nutricio´n Salvador Zubira´n, Vasco de Quiroga 15, Tlalpan, 14080 Mexico City, Mexico.
    [Show full text]
  • Plant Protease Inhibitors: a Defense Strategy in Plants
    Biotechnology and Molecular Biology Review Vol. 2 (3), pp. 068-085, August 2007 Available online at http://www.academicjournals.org/BMBR ISSN 1538-2273 © 2007 Academic Journals Standard Review Plant protease inhibitors: a defense strategy in plants Huma Habib and Khalid Majid Fazili* Department of Biotechnology, The University of Kashmir, P/O Naseembagh, Hazratbal, Srinagar -190006, Jammu and Kashmir, India. Accepted 7 July, 2007 Proteases, though essentially indispensable to the maintenance and survival of their host organisms, can be potentially damaging when overexpressed or present in higher concentrations, and their activities need to be correctly regulated. An important means of regulation involves modulation of their activities through interaction with substances, mostly proteins, called protease inhibitors. Some insects and many of the phytopathogenic microorganisms secrete extracellular enzymes and, in particular, enzymes causing proteolytic digestion of proteins, which play important roles in pathogenesis. Plants, however, have also developed mechanisms to fight these pathogenic organisms. One important line of defense that plants have to fight these pathogens is through various inhibitors that act against these proteolytic enzymes. These inhibitors are thus active in endogenous as well as exogenous defense systems. Protease inhibitors active against different mechanistic classes of proteases have been classified into different families on the basis of significant sequence similarities and structural relationships. Specific protease inhibitors are currently being overexpressed in certain transgenic plants to protect them against invaders. The current knowledge about plant protease inhibitors, their structure and their role in plant defense is briefly reviewed. Key words: Proteases, enzymes, protease inhibitors, serpins, cystatins, pathogens, defense. Table of content 1.
    [Show full text]
  • Effect of Statins and ACE Inhibitors Alone and in Combination on Clinical Outcome in Patients with Coronary Heart Disease
    Journal of Human Hypertension (2004) 18, 781–788 & 2004 Nature Publishing Group All rights reserved 0950-9240/04 $30.00 www.nature.com/jhh ORIGINAL ARTICLE Effect of statins and ACE inhibitors alone and in combination on clinical outcome in patients with coronary heart disease VG Athyros1, DP Mikhailidis3, AA Papageorgiou2, VI Bouloukos1, AN Pehlivanidis1, AN Symeonidis4 and M Elisaf5, for the GREACE Study Collaborative Group 1Atherosclerosis Unit, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; 2Department of Clinical Biochemistry, Royal Free Hospital, Royal Free and University College Medical School, Pond Street, London, UK; 32nd Propedeutic Department of Internal Medicine, Aristotelian University, Hippocration Hospital, Thessaloniki, Greece; 4Greek Society of General Practitioners, Thessaloniki, Greece; 5Department of Internal Medicine, Medical School, University of Ioannina, Greece We assessed the ‘synergy’ of statins and angiotensin- point in group A was 31%, (95% CI À48 to À6%, P ¼ 0.01) converting enzyme inhibitors (ACEI) in reducing vascu- in comparison to group B, 59% (95% CI À72 to À48%, lar events in patients with coronary heart disease (CHD). Po0.0001) to group C and 63% (95% CI À74 to À51%, The GREek Atorvastatin and CHD Evaluation (GREACE) Po0.0001) to group D. There was no significant Study, suggested that aggressive reduction of low difference in RRR between groups C and D (9%, CI density lipoprotein cholesterol to 2.59 mmol/l À27–10%, P ¼ 0.1). Other factors (eg the blood pressure) (o100 mg/dl) significantly reduces morbidity and mor- that can influence clinical outcome did not differ tality in CHD patients, in comparison to undertreated significantly between the four treatment groups.
    [Show full text]
  • Legionella Genus Genome Provide Multiple, Independent Combinations for Replication in Human Cells
    Supplemental Material More than 18,000 effectors in the Legionella genus genome provide multiple, independent combinations for replication in human cells Laura Gomez-Valero1,2, Christophe Rusniok1,2, Danielle Carson3, Sonia Mondino1,2, Ana Elena Pérez-Cobas1,2, Monica Rolando1,2, Shivani Pasricha4, Sandra Reuter5+, Jasmin Demirtas1,2, Johannes Crumbach1,2, Stephane Descorps-Declere6, Elizabeth L. Hartland4,7,8, Sophie Jarraud9, Gordon Dougan5, Gunnar N. Schroeder3,10, Gad Frankel3, and Carmen Buchrieser1,2,* Table S1: Legionella strains analyzed in the present study Table S2: Type IV secretion systems predicted in the genomes analyzed Table S3: Eukaryotic like domains identified in the Legionella proteins analyzed Table S4: Small GTPases domains detected in the genus Legionella as defined in the CDD ncbi domain database Table S5: Eukaryotic like proteins detected in the Legionella genomes analyzed in this study Table S6: Aminoacid identity of the Dot/Icm components in Legionella species with respect to orthologous proteins in L. pneumophila Paris Table S7: Distribution of seventeen highly conserved Dot/Icm secreted substrates Table S8: Comparison of the effector reperotoire among strains of the same Legionella species Table S9. Number of Dot/Icm secreted proteins predicted in each strain analyzed Table S10: Replication capacity of the different Legionella species analyzed in this study and collection of literature data on Legionella replication Table S11: Orthologous table for all genes of the 80 analyzed strains based on PanOCT. The orthologoss where defined with the program PanOCT using the parameters previously indicated in material and methods.) Figure S1: Distribution of the genes predicted to encode for the biosynthesis of flagella among all Legionella species.
    [Show full text]
  • A Shunt Pathway Limits the Caax Processing of Hsp40 Ydj1p and Regulates Ydj1p-Dependent
    1 TITLE 2 A shunt pathway limits the CaaX processing of Hsp40 Ydj1p and regulates Ydj1p-dependent 3 phenotypes 4 Emily R. Hildebrandt, Michael Cheng, Peng Zhao, June H. Kim, Lance Wells, and Walter K. 5 Schmidt* 6 Department of Biochemistry and Molecular Biology, The University of Georgia, Athens, GA 7 30602, USA 8 *corresponding author: Walter K. Schmidt, 706-583-8241 (phone), 706-542-1738 (fax), 9 [email protected] (email) 10 11 COMPETING INTERESTS: none 12 13 Key words: CaaX, isoprenylation, HSP40, chaperone, thermotolerance 14 15 ABBREVIATIONS 16 polyacrylamide gel electrophoresis (PAGE) 17 sodium dodecyl sulfate (SDS) 18 heat shock protein 40 (Hsp40) 19 20 ABSTRACT 21 The modifications occurring to CaaX proteins have largely been established using few reporter 22 molecules (e.g. Ras, yeast a-factor mating pheromone). These proteins undergo three 23 coordinated COOH-terminal events: isoprenylation of the cysteine, proteolytic removal of aaX, 24 and COOH-terminal methylation. Here, we investigated the coupling of these modifications in 25 the context of the yeast Ydj1p chaperone. We provide genetic, biochemical, and biophysical 26 evidence that the Ydj1p CaaX motif is isoprenylated but not cleaved and carboxylmethylated. 27 Moreover, we demonstrate that Ydj1p-dependent thermotolerance and Ydj1p localization are 28 perturbed when alternative CaaX motifs are transplanted onto Ydj1p. The abnormal 29 phenotypes revert to normal when post-isoprenylation events are genetically interrupted. Our 30 findings indicate that proper Ydj1p function requires an isoprenylatable CaaX motif that is 31 resistant to post-isoprenylation events. These results expand on the complexity of protein 32 isoprenylation and highlight the impact of post-isoprenylation events in regulating the function of 33 Ydj1p and perhaps other CaaX proteins.
    [Show full text]
  • A Small-Molecule Inhibitor of Isoprenylcysteine Carboxyl Methyltransferase with Antitumor Activity in Cancer Cells
    A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells Ann M. Winter-Vann*, Rudi A. Baron*, Waihay Wong*, June dela Cruz*, John D. York*, David M. Gooden†, Martin O. Bergo‡, Stephen G. Young§, Eric J. Toone†, and Patrick J. Casey*¶ Departments of *Pharmacology and Cancer Biology and †Chemistry, Duke University Medical Center, Durham, NC 27710; ‡Department of Internal Medicine, Sahlgrenska University Hospital, S-413 45 Gothenburg, Sweden; and §Department of Medicine, University of California, Los Angeles, CA 90095 Edited by John A. Glomset, University of Washington, Seattle, WA, and approved February 7, 2005 (received for review November 1, 2004) Many key regulatory proteins, including members of the Ras family proteins have also been implicated in oncogenesis and tumor of GTPases, are modified at their C terminus by a process termed progression, and these proteins most likely require processing via prenylation. This processing is initiated by the addition of an the prenylation pathway for function (2, 15). isoprenoid lipid, and the proteins are further modified by a pro- Both the membrane targeting and the transforming abilities of teolytic event and methylation of the C-terminal prenylcysteine. Ras require processing through the prenylation pathway (16, 17). Although the biological consequences of prenylation have been For this reason, the protein prenyltransferases, most notably characterized extensively, the contributions of prenylcysteine FTase, have been targets of major drug discovery programs for methylation to the functions of the modified proteins are not well the last decade (18, 19). Presently, several FTase inhibitors are understood. This reaction is catalyzed by the enzyme isoprenyl- being evaluated in clinical trials (15, 19).
    [Show full text]
  • Onc2016508.Pdf
    OPEN Oncogene (2017) 36, 3934–3942 www.nature.com/onc SHORT COMMUNICATION Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms HY Lau1, J Tang1, PJ Casey1 and M Wang1,2 Despite extensive effort, there has been limited progress in the development of direct RAS inhibitors. Targeting isoprenylcysteine carboxylmethyltransferase (ICMT), a unique enzyme of RAS post-translational modification, represents a promising strategy to inhibit RAS function. However, there lacks direct genetic evidence on the role of ICMT in RAS-driven human cancer initiation and maintenance. Using CRISPR/Cas9 genome editing, we have created Icmt loss-of-function isogenic cell lines for both RAS- transformed human mammary epithelial cells (HME1) and human cancer cell lines MiaPaca-2 and MDA-MB-231 containing naturally occurring mutant KRAS. In both in vitro and in vivo tumorigenesis studies, Icmt loss-of-function abolishes the tumor initiation ability of all major isoforms of mutant RAS in HME1 cells, and the tumor maintenance capacity of MiaPaca-2 and MDA-MB-231 cells, establishing the critical role of ICMT in RAS-driven cancers. Oncogene (2017) 36, 3934–3942; doi:10.1038/onc.2016.508; published online 13 February 2017 INTRODUCTION driven transformation and maintenance. Another important Constitutively active mutations of RAS are the most common unanswered question in this field is whether ICMT inhibition driving mutations in human cancers,1,2 with up to 90% of invasive impacts tumorigenic processes driven by different RAS isoforms, pancreatic ductal adenocarcinomas harboring activating KRAS since most studies have been done on KRAS up to this point.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces Sp. CNQ-027
    J. Microbiol. Biotechnol. (2017), 27(4), 785–790 https://doi.org/10.4014/jmb.1612.12025 Research Article Review jmb Potent Inhibition of Monoamine Oxidase B by a Piloquinone from Marine-Derived Streptomyces sp. CNQ-027 Hyun Woo Lee1, Hansol Choi2, Sang-Jip Nam2, William Fenical3, and Hoon Kim1* 1Department of Pharmacy and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Republic of Korea 2Department of Chemistry and Nano Science, Ewha Womans University, Seoul 03760, Republic of Korea 3Center for Marine Biotechnology and Biomedicine, Scripps Institution of Oceanography, University of California, San Diego, La Jolla, CA 92093-0204, USA Received: December 19, 2016 Revised: December 27, 2016 Two piloquinone derivatives isolated from Streptomyces sp. CNQ-027 were tested for the Accepted: January 4, 2017 inhibitory activities of two isoforms of monoamine oxidase (MAO), which catalyzes monoamine neurotransmitters. The piloquinone 4,7-dihydroxy-3-methyl-2-(4-methyl-1- oxopentyl)-6H-dibenzo[b,d]pyran-6-one (1) was found to be a highly potent inhibitor of First published online human MAO-B, with an IC50 value of 1.21 µM; in addition, it was found to be highly effective January 9, 2017 against MAO-A, with an IC50 value of 6.47 µM. Compound 1 was selective, but not extremely *Corresponding author so, for MAO-B compared with MAO-A, with a selectivity index value of 5.35. Compound 1,8- Phone: +82-61-750-3751; dihydroxy-2-methyl-3-(4-methyl-1-oxopentyl)-9,10-phenanthrenedione (2) was moderately Fax: +82-61-750-3708; effective for the inhibition of MAO-B (IC = 14.50 µM) but not for MAO-A (IC > 80 µM).
    [Show full text]
  • Kinase-Targeted Cancer Therapies: Progress, Challenges and Future Directions Khushwant S
    Bhullar et al. Molecular Cancer (2018) 17:48 https://doi.org/10.1186/s12943-018-0804-2 REVIEW Open Access Kinase-targeted cancer therapies: progress, challenges and future directions Khushwant S. Bhullar1, Naiara Orrego Lagarón2, Eileen M. McGowan3, Indu Parmar4, Amitabh Jha5, Basil P. Hubbard1 and H. P. Vasantha Rupasinghe6,7* Abstract The human genome encodes 538 protein kinases that transfer a γ-phosphate group from ATP to serine, threonine, or tyrosine residues. Many of these kinases are associated with human cancer initiation and progression. The recent development of small-molecule kinase inhibitors for the treatment of diverse types of cancer has proven successful in clinical therapy. Significantly, protein kinases are the second most targeted group of drug targets, after the G-protein- coupled receptors. Since the development of the first protein kinase inhibitor, in the early 1980s, 37 kinase inhibitors have received FDA approval for treatment of malignancies such as breast and lung cancer. Furthermore, about 150 kinase-targeted drugs are in clinical phase trials, and many kinase-specific inhibitors are in the preclinical stage of drug development. Nevertheless, many factors confound the clinical efficacy of these molecules. Specific tumor genetics, tumor microenvironment, drug resistance, and pharmacogenomics determine how useful a compound will be in the treatment of a given cancer. This review provides an overview of kinase-targeted drug discovery and development in relation to oncology and highlights the challenges and future potential for kinase-targeted cancer therapies. Keywords: Kinases, Kinase inhibition, Small-molecule drugs, Cancer, Oncology Background Recent advances in our understanding of the fundamen- Kinases are enzymes that transfer a phosphate group to a tal molecular mechanisms underlying cancer cell signaling protein while phosphatases remove a phosphate group have elucidated a crucial role for kinases in the carcino- from protein.
    [Show full text]
  • Genome-Wide Association and Gene Enrichment Analyses of Meat Sensory Traits in a Crossbred Brahman-Angus
    Proceedings of the World Congress on Genetics Applied to Livestock Production, 11. 124 Genome-wide association and gene enrichment analyses of meat tenderness in an Angus-Brahman cattle population J.D. Leal-Gutíerrez1, M.A. Elzo1, D. Johnson1 & R.G. Mateescu1 1 University of Florida, Department of Animal Sciences, 2250 Shealy Dr, 32608 Gainesville, Florida, United States. [email protected] Summary The objective of this study was to identify genomic regions associated with meat tenderness related traits using a whole-genome scan approach followed by a gene enrichment analysis. Warner-Bratzler shear force (WBSF) was measured on 673 steaks, and tenderness and connective tissue were assessed by a sensory panel on 496 steaks. Animals belong to the multibreed Angus-Brahman herd from University of Florida and range from 100% Angus to 100% Brahman. All animals were genotyped with the Bovine GGP F250 array. Gene enrichment was identified in two pathways; the first pathway is involved in negative regulation of transcription from RNA polymerase II, and the second pathway groups several cellular component of the endoplasmic reticulum membrane. Keywords: tenderness, gene enrichment, regulation of transcription, cell growth, cell proliferation Introduction Identification of quantitative trait loci (QTL) for any complex trait, including meat tenderness, is the first most important step in the process of understanding the genetic architecture underlying the phenotype. Given a large enough population and a dense coverage of the genome, a genome-wide association study (GWAS) is usually successful in uncovering major genes and QTLs with large and medium effect on these type of traits. Several GWA studies on Bos indicus (Magalhães et al., 2016; Tizioto et al., 2013) or crossbred beef cattle breeds (Bolormaa et al., 2011b; Hulsman Hanna et al., 2014; Lu et al., 2013) were successful at identifying QTL for meat tenderness; and most of them include the traditional candidate genes µ-calpain and calpastatin.
    [Show full text]
  • Evidence of Pyrimethamine and Cycloguanil Analogues As Dual Inhibitors of Trypanosoma Brucei Pteridine Reductase and Dihydrofolate Reductase
    pharmaceuticals Article Evidence of Pyrimethamine and Cycloguanil Analogues as Dual Inhibitors of Trypanosoma brucei Pteridine Reductase and Dihydrofolate Reductase Giusy Tassone 1,† , Giacomo Landi 1,†, Pasquale Linciano 2,† , Valeria Francesconi 3 , Michele Tonelli 3 , Lorenzo Tagliazucchi 2 , Maria Paola Costi 2 , Stefano Mangani 1 and Cecilia Pozzi 1,* 1 Department of Biotechnology, Chemistry and Pharmacy, Department of Excellence 2018–2022, University of Siena, via Aldo Moro 2, 53100 Siena, Italy; [email protected] (G.T.); [email protected] (G.L.); [email protected] (S.M.) 2 Department of Life Science, University of Modena and Reggio Emilia, via Campi 103, 41125 Modena, Italy; [email protected] (P.L.); [email protected] (L.T.); [email protected] (M.P.C.) 3 Department of Pharmacy, University of Genoa, Viale Benedetto XV n.3, 16132 Genoa, Italy; [email protected] (V.F.); [email protected] (M.T.) * Correspondence: [email protected]; Tel.: +39-0577-232132 † These authors contributed equally to this work. Abstract: Trypanosoma and Leishmania parasites are the etiological agents of various threatening Citation: Tassone, G.; Landi, G.; neglected tropical diseases (NTDs), including human African trypanosomiasis (HAT), Chagas disease, Linciano, P.; Francesconi, V.; Tonelli, and various types of leishmaniasis. Recently, meaningful progresses in the treatment of HAT, due to M.; Tagliazucchi, L.; Costi, M.P.; Trypanosoma brucei (Tb), have been achieved by the introduction of fexinidazole and the combination Mangani, S.; Pozzi, C. Evidence of therapy eflornithine–nifurtimox. Nevertheless, due to drug resistance issues and the exitance of Pyrimethamine and Cycloguanil animal reservoirs, the development of new NTD treatments is still required.
    [Show full text]